DDR1 inhibition as a new therapeutic strategy for colorectal cancer

The clinical management of metastatic colorectal cancer (mCRC) is still a major challenge. Recently, we discovered that nilotinib, an approved treatment for chronic myeloid leukaemia, inhibits invasive and metastatic properties of CRC cells by targeting the kinase activity of receptor for collagens...

Descripción completa

Detalles Bibliográficos
Autores principales: Sirvent, Audrey, Lafitte, Marie, Roche, Serge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Author's Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149912/
https://www.ncbi.nlm.nih.gov/pubmed/30250919
http://dx.doi.org/10.1080/23723556.2018.1465882
_version_ 1783356895440928768
author Sirvent, Audrey
Lafitte, Marie
Roche, Serge
author_facet Sirvent, Audrey
Lafitte, Marie
Roche, Serge
author_sort Sirvent, Audrey
collection PubMed
description The clinical management of metastatic colorectal cancer (mCRC) is still a major challenge. Recently, we discovered that nilotinib, an approved treatment for chronic myeloid leukaemia, inhibits invasive and metastatic properties of CRC cells by targeting the kinase activity of receptor for collagens DDR1 (Discoïdin Domain Receptor tyrosine kinase 1), suggesting that nilotinib could be an effective strategy to treat mCRC.
format Online
Article
Text
id pubmed-6149912
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-61499122019-07-23 DDR1 inhibition as a new therapeutic strategy for colorectal cancer Sirvent, Audrey Lafitte, Marie Roche, Serge Mol Cell Oncol Author's Views The clinical management of metastatic colorectal cancer (mCRC) is still a major challenge. Recently, we discovered that nilotinib, an approved treatment for chronic myeloid leukaemia, inhibits invasive and metastatic properties of CRC cells by targeting the kinase activity of receptor for collagens DDR1 (Discoïdin Domain Receptor tyrosine kinase 1), suggesting that nilotinib could be an effective strategy to treat mCRC. Taylor & Francis 2018-07-23 /pmc/articles/PMC6149912/ /pubmed/30250919 http://dx.doi.org/10.1080/23723556.2018.1465882 Text en © 2018 The Author(s). Published by Taylor & Francis. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Author's Views
Sirvent, Audrey
Lafitte, Marie
Roche, Serge
DDR1 inhibition as a new therapeutic strategy for colorectal cancer
title DDR1 inhibition as a new therapeutic strategy for colorectal cancer
title_full DDR1 inhibition as a new therapeutic strategy for colorectal cancer
title_fullStr DDR1 inhibition as a new therapeutic strategy for colorectal cancer
title_full_unstemmed DDR1 inhibition as a new therapeutic strategy for colorectal cancer
title_short DDR1 inhibition as a new therapeutic strategy for colorectal cancer
title_sort ddr1 inhibition as a new therapeutic strategy for colorectal cancer
topic Author's Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149912/
https://www.ncbi.nlm.nih.gov/pubmed/30250919
http://dx.doi.org/10.1080/23723556.2018.1465882
work_keys_str_mv AT sirventaudrey ddr1inhibitionasanewtherapeuticstrategyforcolorectalcancer
AT lafittemarie ddr1inhibitionasanewtherapeuticstrategyforcolorectalcancer
AT rocheserge ddr1inhibitionasanewtherapeuticstrategyforcolorectalcancer

Ejemplares similares